Theravance Biopharma, Inc.
Theravance Biopharma is a U.S.-based biopharmaceutical company focused on developing and commercializing medicines for respiratory and other specialty indications. Its portfolio includes an approved COPD therapy, YUPELRI, and a late-stage investigational program, ampreloxetine, supported through a mix of internal development and collaboration arrangements.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved inhaled therapy sold for maintenance treatment of COPD.
Revenue earned from partnered commercialization and licensing arrangements.
Upfront or milestone-based licensing income from partnered assets.
Tuotteet
Raportoitu · osuus liikevaihdosta- Collaborative Arrangement Revenue69,8 %
- Milestone23,3 %
- License7,0 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Theravance Biopharma sells into the respiratory care market through healthcare providers, physicians, distributors, and third-party payors. Its commercial product is used by COPD patients who need or prefer nebulized maintenance therapy, while its development programs target specialty neurology and autonomic-disorder populations through future prescribing channels.
Buy and prescribe YUPELRI for maintenance treatment of COPD, especially where nebulized delivery is preferred.
Influence access, reimbursement, and formulary placement for YUPELRI and future products.
Handle prescribing, dispensing, and distribution of the company’s commercial product.
Collaborate on commercialization, milestones, royalties, and licensing arrangements.
Potential future users of ampreloxetine if approved for symptomatic nOH in MSA.
Strategia
The company’s strategy centers on sustaining YUPELRI’s commercial position while advancing ampreloxetine through late-stage development. It also relies on collaboration structures to extend reach, monetize partnered assets, and reduce the capital intensity of building a larger commercial footprint.
Commercial revenue depends on physician, patient, and payor acceptance of the COPD product.
A successful late-stage program could add a new specialty medicine and diversify the portfolio.
Partnered arrangements provide non-dilutive revenue and reduce direct commercialization burden.
Maantiede
2025Theravance Biopharma is headquartered in the United States and its commercial focus is primarily the U.S. COPD market. The company also has economic exposure to global partner commercialization through royalty and milestone arrangements, which can broaden its revenue base beyond direct product sales.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Theravance Biopharma is exposed to concentration risk because a large part of its business depends on YUPELRI and on partner execution in commercialization and royalties. Its development pipeline also carries the usual biotechnology risks of clinical failure, regulatory delay, manufacturing dependence, and reimbursement pressure in a highly regulated market.
- Dependence on YUPELRI commercializationVaikutus: KorkeaTodennäköisyys: Korkea
A meaningful share of the company’s business is tied to one approved COPD product.
Kohdistuu: YUPELRI sales and related collaboration revenue
- Clinical development failure for ampreloxetineVaikutus: KorkeaTodennäköisyys: Korkea
Late-stage drug candidates can fail on efficacy, safety, or regulatory grounds.
Kohdistuu: Pipeline value and future product diversification
- Manufacturing and supply chain concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on single suppliers for YUPELRI API, drug product, and warehousing.
Kohdistuu: Product availability and regulatory compliance
- Reimbursement and healthcare regulationVaikutus: KeskitasoTodennäköisyys: Korkea
Payor coverage, anti-kickback rules, and pricing controls affect market access.
Kohdistuu: U.S. pharmaceutical commercialization
- Partner dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Milestones, royalties, and commercialization outcomes depend on third-party partners.
Kohdistuu: Viatris and other collaboration arrangements
Kirjanpito
Harkinnanvaraiset erätRevenue may depend on performance obligations, milestones, and partner activity.
Vaikutus: Can create uneven quarterly revenue recognition
Receipts from partners may be recognized based on contractual triggers rather than direct sales.
Vaikutus: Can cause volatility in reported revenue
Management cites tax, litigation, and indemnification matters as future cash and earnings risks.
Vaikutus: May require accruals or disclosures
Clinical-stage programs require judgment on recoverability and future economic benefit.
Vaikutus: Could affect impairment assessments and balance sheet values
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Spero Therapeutics, Inc.
SPRO · Pharmaceutical Preparations
Pulmatrix, Inc.
PULM · Pharmaceutical Preparations
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
United Therapeutics Corporation
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Arrowhead Pharmaceuticals, Inc
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
Päivitetty: 24.9.2026